Efatutazone, an oral PPAR- γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: Results of a multicenter phase 1 trial

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2392-2400

  Smallridge, Robert C ^a   Copland, J A ^a   Brose, M S ^b   Wadsworth, J T ^c   Houvras, Y ^d   Menefee, M E ^a   Bible, K C ^e   Shah, M H ^f   Gramza, A W ^g   Klopper, J P ^h   Marlow, L A ^a   Heckman, M G ^a   Von Roemeling, R ⁱ  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e MAYO CLINIC   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; EFATUTAZONE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHYLAXIS; ANAPLASTIC THYROID CANCER; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM INFECTION; CONFUSION; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EDEMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; SEPTIC SHOCK; SURVIVAL TIME;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PACLITAXEL; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID NEOPLASMS;

EID: 84878483846     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1106     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22:486-497.
3. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028-1034. (Pubitemid 34014569)
4. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10:587-594. (Pubitemid 30670619)
5. Kawada K, Kitagawa K, Kamei S, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol. 2010;40:596-599.
6. Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95:E54-E57.
7. Hogan T, Yu JJ, Williams HJ, Altaha R, Liang X, He Q. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009;15:111-117.
8. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975-980.
9. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19:233-240.
10. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17-44.
11. Theocharis S, Margeli A, Vielh P, Kouraklis G. Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators. Cancer Treat Rev. 2004;30:545-554. (Pubitemid 39157854)
12. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419-429. (Pubitemid 38878045)
13. Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor γ agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer. 2008;44:1734-1743.
14. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor γ agonist, administered to patients with advanced malignancies. Cancer. 2012;118:5403-5413.
15. WAF1/CIP1. Oncogene. 2006;25:2304-2317.
16. Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009;69:1536-1544.
17. Prendergast GC. Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer. 2001;1:162-168. (Pubitemid 33741892)
18. Kobayashi T, Asakawa H, Umeshita K, et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck. 1996;18:36-41. (Pubitemid 26002035)
19. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66:321-330. (Pubitemid 20205915)
20. Voutilainen PE, Multanen M, Haapiainen RK, Leppäniemi AK, Sivula AH. Anaplastic thyroid carcinoma survival. World J Surg. 1999;23:975-978; discussion 978-979.
21. Wood WM, Sharma V, Bauerle KT, et al. PPARγ promotes growth and invasion of thyroid cancer cells. PPAR Res. 2011;2011:171765.
22. Shaw A, Ghizdavescu D, Jain M, et al. Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC). Presented at American Association for Cancer Research; March 31-April 4, 2012, Chicago, IL.